<DOC>
	<DOCNO>NCT00517790</DOCNO>
	<brief_summary>The purpose study evaluate effect ABT-869 NSCLC subject .</brief_summary>
	<brief_title>Study ABT-869 Subjects With Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Subject must histologically cytologically diagnose advanced metastatic NSCLC Subjects must least one lesion measurable CT scan define RECIST The measurable lesion may receive radiation therapy Subject Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 Subject receive least one prior line systemic treatment two treatment regimen ( ) advance metastatic NSCLC . In addition , subject may receive systemic neoadjuvant adjuvant chemotherapy NSCLC Adequate organ function Subject receive targeted VEGF/PDGF TKI ( tyrosine kinase inhibitor ) therapy . Prior Avastin allow . Subject untreated brain meningeal metastasis . History great 10 % weight loss Subject clinically relevant hemoptysis The subject proteinuria CTC Grade &gt; 1 The subject currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure &gt; 100 mmHg systolic blood pressure &gt; 150 mmHg . Subjects may rescreened blood pressure show control without intervention . The subject document leave ventricular ejection fraction &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Refractory</keyword>
	<keyword>Metastatic</keyword>
</DOC>